Skip to content

MaxCyte MXCT Cash Flow Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$39.12M+6.4%-$44.63M-8.7%-$45.63M-27.7%-$44.77M-26.4%-$41.79M-14.3%
$4.29M-0.2%$4.34M+0.6%$4.33M-0.8%$4.32M-1.3%$4.3M-0.5%
$7.32M-44.2%$9.21M-29.6%$11.64M-13.9%$13.06M-5.1%$13.11M-4.4%
-$28.17M+10.5%-$34.41M-24.6%-$39.54M-99.8%-$36.48M-54.3%-$31.46M-8.8%
$1.19M-20.9%$1.77M+7.1%$1.68M-30.4%$1.79M-34.5%$1.5M-49.1%
$19.06M$25.94M
$278K-84.0%$656K-68.1%$963K-54.9%$1.18M-39.5%$1.74M+24.9%
-$23.99M-$22.29M
-$29.36M+10.9%-$36.18M-23.6%-$41.23M-93.6%-$38.27M-50.3%-$32.96M-6.5%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does MaxCyte generate?
MaxCyte (MXCT) generated -$28.2M in operating cash flow over the trailing twelve months.
What is MaxCyte's free cash flow?
After $1.2M of capital expenditures, MaxCyte's free cash flow was -$29.4M over the trailing twelve months, up 10.9% year over year.
Where does MaxCyte's cash flow data come from?
Every line is extracted from MaxCyte's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.